EPZ011989 [72], another selective and orally bioavailable EZH2 inhibitor reported in 2015, was able to inhibit tumor growth significantly in a mouse xenograft model of human B cell lymphoma. The gene discussed is EZH2; the disease is B-cell non-Hodgkin lymphoma.